- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05915117
Effects of Polyphenols of Pomegranate Fruit Peel Extract on Inflammation and Oxidative Stress in Metabolic Syndrome
Randomized, Double-blind, Placebo-controlled Study of Efficacy Polyphenols of Pomegranate Fruit Peel Extract on Inflammatory Parameters and Oxidative Stress in Overweight and Obese Subjects With Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, randomized, double-blind, placebo-controlled evaluation of the efficacy of polyphenols of pomegranate fruit peel extract on oxidative stress and inflammation in overweight and obese subjects with metabolic syndrome.
Study site: a single study center (Primary Health Care Institution in Banja Luka, as recruiter center) as recruitment center including Center for Biomedical Research, Faculty of Medicine University of Banja Luka, as local laboratory and coordinator.
Sample size: 60 subjects, randomized in a 1:1 allocation ratio.
Primary objectives are to investigate an effect of polyphenols pomegranate fruit peel extract on: Anthropometric parameters such as body mass index, and arterial blood pressure, glycemia, lipoprotein profile, homeostatic model assessment for insulin resistance (HOMAIR), homocysteine, vitamin B complex: folic acid, vitamin B6, vitamin B9 and vitamin B12.
2. To investigate the effects polyphenols from pomegranate fruit peel extract has on impact on lipid peroxidation index, nitric oxide metabolites, hydrogen peroxide (H2O2), superoxide anion radical (O2-), and glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD).
3. Proinflammatory markers interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high sensitive CRP (hsCRP), leptin, resistin ,vaspin, chemerin, lipokalin-2 and katepsin .
4. Anti-infammatory markers IL-5, IL-10, IL-12 ,adiponectin and omentin.
Treatments arms:
Polyphenols of pomegranate fruit peel extract (PoPeEx) (500 mg/day) Placebo
Treatment duration :
8 weeks
Assessment - clinical and laboratory sampling:
Informed consent and Screening - 7 days prior to randomization
Study visits (V):
V1 - Randomization and Enrollment (Baseline) V2 - 4 weeks after Baseline V3 - 8 weeks after Baseline.
No interim analysis is planned. The analysis will be performed at the end of the study after data review and freezing of the database according to the intent to treat principle.
- Page 2 of 6 [DRAFT] -
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Republic Of Srpska
-
Banja Luka, Republic Of Srpska, Bosnia and Herzegovina, 78000
- Public Health Institution Dom zdravlja Banja Luka
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Informed consent signed Adults of 20 to 60 years BMI ≥ 25.00 kg/m2
Met criteria for metabolic syndrome such as visceral obesity( for men ≥ 94 cm and ≥ 80 cm for women) and at least two risk factors:
- TG ≥ 1,7 mmol/l, or present therapy for dyslipidemia
- HDL <1,03 mmol/l men, <1,29 mmol/l women
- Arterial blood pressure ≥130/85 mmHg
- Glycemia ≥ 5.6 mmol/l and < 6.9 mmol/l
Exclusion Criteria:
Subjects with malignant and other acute and chronic infectious and non-infectious disease requiring active pharmacotherapy.
Subjects with with insulin dependent diabetes mellitus or subjects with insulin independent diabetes mellitus taking oral hypoglycemic therapy Subjects with uncontrolled chronic cardiovascular, endocrine, autoimmune, psychiatric, and autoimmune diseases or other condition based on the investigator judgement.
Non adherent subject Systematic use of corticosteroids Pregnant or lactating women Chronic use of supplements (omega 3 unsaturated acids, silymarin, mineral-vitamin supplements) Participation in any other interventional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Polyphenols of pomegranate fruit peel extract (PoPex)
All subjects will treated only with PoPex in total daily dosis of 500 mg/orally over 8 weeks.
|
PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
Other Names:
|
Placebo Comparator: Placebo
All subjects will treated only with PoPex placebo capsules/orally over 8 weeks
|
Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oxidative stress biomarkers levels: lipid peroxidation index, nitric oxide metabolites, hydrogen peroxide (H2O2), superoxide anion radical (O2-), and glutation (GSH), catalasis(CAT) and superoxid dismutasis(SOD).
Time Frame: From Baseline and after 8 weeks
|
ELISA assey
|
From Baseline and after 8 weeks
|
Change in proinflammatori parametars:interleukin-6 (IL-6), tumor necrosis factor-α (TNF- α), high sensitive CRP (hsCRP), leptin, resistin ,vaspin, chemerin ,lipokalin -2 and katepsin
Time Frame: From Baseline and after 8 weeks
|
ELISA assey
|
From Baseline and after 8 weeks
|
Change in antiinflammatori parametars:interleukin -5 (IL-5) ,interleukin-10(IL-10), interleukin-12 (IL-12) ,adiponectin and omentin
Time Frame: From Baseline and after 8 weeks
|
ELISA assey
|
From Baseline and after 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in inflammation marker level : high sensitivity CRP Turbid mertic test
Time Frame: From Baseline and after 8 weeks
|
Turbid metric test
|
From Baseline and after 8 weeks
|
Change in total choleterol (TC), low -density lipoprotein ( LDL), high-density lipoprotein (HDL) and trglicerides Turbid mertic test
Time Frame: From Baseline,after 4 and 8 weeks
|
Clinical biochemistry (colorimetric) test and results will be expressed in mmol/l
|
From Baseline,after 4 and 8 weeks
|
Change in serum levels homocystein
Time Frame: From Baseline,after 4 and 8 weeks
|
Detection by fluoroscence polarization immunoassay
|
From Baseline,after 4 and 8 weeks
|
Change in serum levels of vitamin B6-piridoxin ,vitamin B9-folic acid ,vitamin B12-cianocobalamin
Time Frame: From Baseline, after 4 and 8 weeks
|
Microparticle enzyme immunoassey
|
From Baseline, after 4 and 8 weeks
|
Change in serum levels of glycemia, insulinemia
Time Frame: From Baseline,after 4 and after 8 weeks
|
glycemia-hexokinase method,insulinemia-ultrasensitivity test,immunoenzyme test:"sandwich"
|
From Baseline,after 4 and after 8 weeks
|
Change in serum levels of liver function tests
Time Frame: From Baseline,after 4 and after 8 weeks
|
IFCC,reference method with pyridoxyl phosphate
|
From Baseline,after 4 and after 8 weeks
|
Change in body weight
Time Frame: From Baseline and after 8 weeks
|
weight ( kg)
|
From Baseline and after 8 weeks
|
Change in systolic and diastolic blood presure
Time Frame: From Baseline and after 8 weeks
|
mm/HG
|
From Baseline and after 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ranko Škrbić, Professor, University of Banja Luka
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PoPexMetSy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Polyphenols of pomegranate fruit peel extract (PoPex)
-
Alexandria UniversityNot yet recruiting
-
University of WashingtonCompletedInflammation | Cardiovascular Disease | End Stage Renal DiseaseUnited States
-
University of AberdeenActive, not recruitingGlucose Metabolism Disorders | Glucose IntoleranceUnited Kingdom
-
Universidade do Vale do SapucaiCompleted
-
Suez Canal UniversityCompleted
-
Seoul National University HospitalUniversity of California, DavisCompletedExercise Tolerance
-
BioActorCompletedOsteoporosis | OsteopeniaPoland
-
Bristol-Myers SquibbCompletedHIV Infections | Cytomegalovirus InfectionsUnited States
-
Stanford UniversityRecruiting
-
University of MichiganCompletedHypertension | Oxidative Stress | Heart Failure With Preserved Ejection Fraction | Diastolic Heart Failure | Hypertensive Heart DiseaseUnited States